Skip to search boxSkip to navigationSkip to main content

Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway

  • Ashutosh Tripathi
    ,
  • Carl Whitehead
    ,
  • Katelyn Surrao
    ,
  • Ananya Pillai
    ,
  • Amit Madeshiya
    ,
  • Yong Li
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Chronic stress is a major risk factor in the pathophysiology of many neuropsychiatric disorders. Further, chronic stress conditions can promote neuroinflammation and inflammatory responses in both humans and animal models. Type I interferons (IFN-I) are critical mediators of the inflammatory response in the periphery and responsible for the altered mood and behavior. However, the underlying mechanisms are not well understood. In the present study, we investigated the role of IFN-I signaling in chronic stress-induced changes in neuroinflammation and behavior. Using the chronic restraint stress model, we found that chronic stress induces a significant increase in serum IFNβ levels in mice, and systemic blockade of IFN-I signaling attenuated chronic stress-induced infiltration of macrophages into prefrontal cortex and behavioral abnormalities. Furthermore, complement component 3 (C3) mediates systemic IFNβ-induced changes in neuroinflammation and behavior. Also, we found significant increases in the mRNA expression levels of IFN-I stimulated genes in the prefrontal cortex of depressed suicide subjects and significant correlation with C3 and inflammatory markers. Together, these findings from animal and human postmortem brain studies identify a crucial role of C3 in IFN-I-mediated changes in neuroinflammation and behavior under chronic stress conditions.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3043-3059 (17 pages)

Journal (Volume, Issue Number)

Molecular Psychiatry (Volume 26, Issue 7)

Publication milestones

  • Accepted/In press - 2021
  • Published - 07/2021

Publication status

Published - 07/2021

ISSN

1359-4184

Publication IDs

  • Scopus: 85104052611
  • PubMed: 33833372

Publication metrics

Metrics

SciVal
Author count
11
SciVal
Paper percentile
81
Fractional count
2
Fractional count
0.18
Fractional count
9
Fractional count
0.82
Fractional count
2
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
58
Citation count
58

Funding Details

Acknowledgements The authors acknowledge the funding support from US National Institute of Health/National Institute of Mental Health (NIMH) grants (MH120876 and MH121959), and the Merit Review Award (BX004758) from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development to AP. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. The research funding support from Augusta University is acknowledged. The authors would like to acknowledge Quebec Suicide Brain Bank for human postmortem tissue samples.
FundersFunding numbers
HSR&D
-
BLR&D, ORD
-
NIH
-
ORD
-Augusta University-
NIMH
R01MH120876, R21MH121959, BX004758
VA
I01BX004758, BX004758